Mersana Therapeutics Stock Today
| MRSN Stock | USD 7.32 0.02 0.27% |
PerformanceWeakest
| Odds Of DistressRisky
|
Mersana Therapeutics is selling at 7.32 as of the 24th of September 2025; that is 0.27 percent decrease since the beginning of the trading day. The stock's open price was 7.34. Mersana Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 26th of June 2025 and ending today, the 24th of September 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of June 2017 | Category Healthcare | Classification Health Care |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates for cancer patients with unmet need. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Mersana Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 4.99 M outstanding shares of which 433.29 K shares are now shorted by private and institutional investors with about 4.15 trading days to cover. More on Mersana Therapeutics
Moving against Mersana Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Mersana Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Martin MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Pharmaceutical Products, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMersana Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mersana Therapeutics' financial leverage. It provides some insight into what part of Mersana Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mersana Therapeutics (MRSN) is traded on NASDAQ Exchange in USA. It is located in 840 Memorial Drive, Cambridge, MA, United States, 02139 and employs 102 people. Mersana Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.68 M. Mersana Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.99 M outstanding shares of which 433.29 K shares are now shorted by private and institutional investors with about 4.15 trading days to cover.
Mersana Therapeutics currently holds about 225.13 M in cash with (82.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32.
Check Mersana Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Mersana Therapeutics is $36.68 Million. Over half of Mersana Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Mersana Ownership Details
Mersana Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| 683 Capital Management Llc | 2025-03-31 | 1.6 M | |
| Jacobs Levy Equity Management, Inc. | 2025-03-31 | 1.3 M | |
| 5am Venture Management, Llc | 2025-03-31 | 1.3 M | |
| Qube Research & Technologies | 2025-03-31 | 1.2 M | |
| Northern Trust Corp | 2025-03-31 | 864.8 K | |
| Renaissance Technologies Corp | 2025-03-31 | 839.9 K | |
| Deutsche Bank Ag | 2025-03-31 | 839.7 K | |
| Ieq Capital, Llc | 2025-03-31 | 707 K | |
| Lion Point Capital, Lp | 2025-03-31 | 644 K | |
| Nextech Invest, Ltd. | 2025-03-31 | 12.1 M | |
| Bain Capital Life Sciences Investors, Llc | 2025-03-31 | 8.7 M |
Mersana Therapeutics Historical Income Statement
Mersana Stock Against Markets
Mersana Therapeutics Corporate Management
| Chuck Miller | Senior Affairs | Profile | |
| Carla Poulson | Chief Officer | Profile | |
| Marc Damelin | Oncology, Biology | Profile | |
| Jason Fredette | Senior Communications | Profile | |
| Mohan Bala | Senior Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share | Quarterly Revenue Growth 0.333 | Return On Assets | Return On Equity |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.